TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis
Background: Transmembrane emp24 domain-containing protein 9 (TMED9) belongs to the TMED/p24 family that transports, modifies, and packs proteins and lipids into vesicles for delivery to specific locations and is important in innate immune signaling via the endoplasmic reticulum–Golgi cargo pathway....
Gespeichert in:
| Veröffentlicht in: | Cancer genomics & proteomics 2022-11, Vol.19 (6), p.692-702 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 702 |
|---|---|
| container_issue | 6 |
| container_start_page | 692 |
| container_title | Cancer genomics & proteomics |
| container_volume | 19 |
| creator | HAN, GWAN HEE YUN, HEE CHUNG, JOON-YONG KIM, JAE-HOON CHO, HANBYOUL |
| description | Background: Transmembrane emp24 domain-containing protein 9 (TMED9) belongs to the TMED/p24 family that transports, modifies, and packs proteins and lipids into vesicles for delivery to specific locations and is important in innate immune signaling via the endoplasmic reticulum–Golgi cargo pathway. TMED9 has been implicated in various cancer types; however, its role in epithelial ovarian cancer (EOC) is unclear. In this study, we aimed to elucidate the role and clinical significance of TMED9 in EOC. Materials and Methods: mRNA and protein levels of TMED9 and their associations with clinicopathological features in EOCs were evaluated using RNA-sequencing and immunohistochemistry data. Functional studies assessing the tumorigenic role of TMED9 in EOC cell lines were also performed. Results: The mRNA expression of TMED9 was up-regulated in EOC compared to that in normal ovarian epithelium. TMED9 protein expression increased in progression from normal ovarian epithelium to EOC (p |
| doi_str_mv | 10.21873/cgp.20352 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9620446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2733415841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-2a5d845f0b8f9a4950d361af37574e228d417b766bc5170a2a69dbd2e41479833</originalsourceid><addsrcrecordid>eNpVUU1LAzEUDKLYWr34CwLehK35zuYiaF0_oFIP9SaE7G62Td1u1mRb9N-71Cp4eu8x82YGBoBzjMYEp5JeFYt2TBDl5AAMsVQoEYTxw37HSCWCUz4AJzGuEGKSMnQMBlRQLBAjQ_A2f87uFMw-22BjdL6BU7u1NTQRGnjr_NqEdxugr2DWum5pa2dqONua4EwDJ6YpevAl-MXvt2nK3d346OIpOKpMHe3Zfo7A6302nzwm09nD0-RmmhSUyS4hhpcp4xXK00oZpjgqqcCmopJLZglJS4ZlLoXIC44lMsQIVeYlsQwzqVJKR-D6R7fd5GtbFrbpgql1G1wf_0t74_R_pHFLvfBbrQRBjIle4GIvEPzHxsZOr_wmNH1mTSSlDPOU4Z51-cMqgo8x2OrPASO9a0L3TehdE_QbkB959g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2733415841</pqid></control><display><type>article</type><title>TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>HAN, GWAN HEE ; YUN, HEE ; CHUNG, JOON-YONG ; KIM, JAE-HOON ; CHO, HANBYOUL</creator><creatorcontrib>HAN, GWAN HEE ; YUN, HEE ; CHUNG, JOON-YONG ; KIM, JAE-HOON ; CHO, HANBYOUL</creatorcontrib><description>Background: Transmembrane emp24 domain-containing protein 9 (TMED9) belongs to the TMED/p24 family that transports, modifies, and packs proteins and lipids into vesicles for delivery to specific locations and is important in innate immune signaling via the endoplasmic reticulum–Golgi cargo pathway. TMED9 has been implicated in various cancer types; however, its role in epithelial ovarian cancer (EOC) is unclear. In this study, we aimed to elucidate the role and clinical significance of TMED9 in EOC. Materials and Methods: mRNA and protein levels of TMED9 and their associations with clinicopathological features in EOCs were evaluated using RNA-sequencing and immunohistochemistry data. Functional studies assessing the tumorigenic role of TMED9 in EOC cell lines were also performed. Results: The mRNA expression of TMED9 was up-regulated in EOC compared to that in normal ovarian epithelium. TMED9 protein expression increased in progression from normal ovarian epithelium to EOC (p<0.001). Moreover, high expression of TMED9 was associated with advanced stage, serous cell type and poor histological grade in EOC and demonstrated independent prognostic significance for both disease-free and overall survival. Further functional studies showed that TMED9 knockdown reduced migration, invasion, cell proliferation, and colony formation of EOC cells. Conclusion: Overall, our results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting of TMED9 as a novel strategy for EOC treatment.</description><identifier>ISSN: 1109-6535</identifier><identifier>EISSN: 1790-6245</identifier><identifier>DOI: 10.21873/cgp.20352</identifier><identifier>PMID: 36316042</identifier><language>eng</language><publisher>Athens: International Institute of Anticancer Research</publisher><subject>Biomarkers ; Cancer ; Cell migration ; Cell proliferation ; Endoplasmic reticulum ; Epithelium ; Gene expression ; Gene sequencing ; Golgi apparatus ; Immunohistochemistry ; Lipids ; Medical prognosis ; Ovarian cancer ; Proteins</subject><ispartof>Cancer genomics & proteomics, 2022-11, Vol.19 (6), p.692-702</ispartof><rights>Copyright International Institute of Anticancer Research Nov/Dec 2022</rights><rights>Copyright 2022, International Institute of Anticancer Research 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-2a5d845f0b8f9a4950d361af37574e228d417b766bc5170a2a69dbd2e41479833</citedby><orcidid>0000-0002-6177-1648</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620446/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620446/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>HAN, GWAN HEE</creatorcontrib><creatorcontrib>YUN, HEE</creatorcontrib><creatorcontrib>CHUNG, JOON-YONG</creatorcontrib><creatorcontrib>KIM, JAE-HOON</creatorcontrib><creatorcontrib>CHO, HANBYOUL</creatorcontrib><title>TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis</title><title>Cancer genomics & proteomics</title><description>Background: Transmembrane emp24 domain-containing protein 9 (TMED9) belongs to the TMED/p24 family that transports, modifies, and packs proteins and lipids into vesicles for delivery to specific locations and is important in innate immune signaling via the endoplasmic reticulum–Golgi cargo pathway. TMED9 has been implicated in various cancer types; however, its role in epithelial ovarian cancer (EOC) is unclear. In this study, we aimed to elucidate the role and clinical significance of TMED9 in EOC. Materials and Methods: mRNA and protein levels of TMED9 and their associations with clinicopathological features in EOCs were evaluated using RNA-sequencing and immunohistochemistry data. Functional studies assessing the tumorigenic role of TMED9 in EOC cell lines were also performed. Results: The mRNA expression of TMED9 was up-regulated in EOC compared to that in normal ovarian epithelium. TMED9 protein expression increased in progression from normal ovarian epithelium to EOC (p<0.001). Moreover, high expression of TMED9 was associated with advanced stage, serous cell type and poor histological grade in EOC and demonstrated independent prognostic significance for both disease-free and overall survival. Further functional studies showed that TMED9 knockdown reduced migration, invasion, cell proliferation, and colony formation of EOC cells. Conclusion: Overall, our results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting of TMED9 as a novel strategy for EOC treatment.</description><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cell migration</subject><subject>Cell proliferation</subject><subject>Endoplasmic reticulum</subject><subject>Epithelium</subject><subject>Gene expression</subject><subject>Gene sequencing</subject><subject>Golgi apparatus</subject><subject>Immunohistochemistry</subject><subject>Lipids</subject><subject>Medical prognosis</subject><subject>Ovarian cancer</subject><subject>Proteins</subject><issn>1109-6535</issn><issn>1790-6245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LAzEUDKLYWr34CwLehK35zuYiaF0_oFIP9SaE7G62Td1u1mRb9N-71Cp4eu8x82YGBoBzjMYEp5JeFYt2TBDl5AAMsVQoEYTxw37HSCWCUz4AJzGuEGKSMnQMBlRQLBAjQ_A2f87uFMw-22BjdL6BU7u1NTQRGnjr_NqEdxugr2DWum5pa2dqONua4EwDJ6YpevAl-MXvt2nK3d346OIpOKpMHe3Zfo7A6302nzwm09nD0-RmmhSUyS4hhpcp4xXK00oZpjgqqcCmopJLZglJS4ZlLoXIC44lMsQIVeYlsQwzqVJKR-D6R7fd5GtbFrbpgql1G1wf_0t74_R_pHFLvfBbrQRBjIle4GIvEPzHxsZOr_wmNH1mTSSlDPOU4Z51-cMqgo8x2OrPASO9a0L3TehdE_QbkB959g</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>HAN, GWAN HEE</creator><creator>YUN, HEE</creator><creator>CHUNG, JOON-YONG</creator><creator>KIM, JAE-HOON</creator><creator>CHO, HANBYOUL</creator><general>International Institute of Anticancer Research</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6177-1648</orcidid></search><sort><creationdate>20221101</creationdate><title>TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis</title><author>HAN, GWAN HEE ; YUN, HEE ; CHUNG, JOON-YONG ; KIM, JAE-HOON ; CHO, HANBYOUL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-2a5d845f0b8f9a4950d361af37574e228d417b766bc5170a2a69dbd2e41479833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cell migration</topic><topic>Cell proliferation</topic><topic>Endoplasmic reticulum</topic><topic>Epithelium</topic><topic>Gene expression</topic><topic>Gene sequencing</topic><topic>Golgi apparatus</topic><topic>Immunohistochemistry</topic><topic>Lipids</topic><topic>Medical prognosis</topic><topic>Ovarian cancer</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAN, GWAN HEE</creatorcontrib><creatorcontrib>YUN, HEE</creatorcontrib><creatorcontrib>CHUNG, JOON-YONG</creatorcontrib><creatorcontrib>KIM, JAE-HOON</creatorcontrib><creatorcontrib>CHO, HANBYOUL</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer genomics & proteomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAN, GWAN HEE</au><au>YUN, HEE</au><au>CHUNG, JOON-YONG</au><au>KIM, JAE-HOON</au><au>CHO, HANBYOUL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis</atitle><jtitle>Cancer genomics & proteomics</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>19</volume><issue>6</issue><spage>692</spage><epage>702</epage><pages>692-702</pages><issn>1109-6535</issn><eissn>1790-6245</eissn><abstract>Background: Transmembrane emp24 domain-containing protein 9 (TMED9) belongs to the TMED/p24 family that transports, modifies, and packs proteins and lipids into vesicles for delivery to specific locations and is important in innate immune signaling via the endoplasmic reticulum–Golgi cargo pathway. TMED9 has been implicated in various cancer types; however, its role in epithelial ovarian cancer (EOC) is unclear. In this study, we aimed to elucidate the role and clinical significance of TMED9 in EOC. Materials and Methods: mRNA and protein levels of TMED9 and their associations with clinicopathological features in EOCs were evaluated using RNA-sequencing and immunohistochemistry data. Functional studies assessing the tumorigenic role of TMED9 in EOC cell lines were also performed. Results: The mRNA expression of TMED9 was up-regulated in EOC compared to that in normal ovarian epithelium. TMED9 protein expression increased in progression from normal ovarian epithelium to EOC (p<0.001). Moreover, high expression of TMED9 was associated with advanced stage, serous cell type and poor histological grade in EOC and demonstrated independent prognostic significance for both disease-free and overall survival. Further functional studies showed that TMED9 knockdown reduced migration, invasion, cell proliferation, and colony formation of EOC cells. Conclusion: Overall, our results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting of TMED9 as a novel strategy for EOC treatment.</abstract><cop>Athens</cop><pub>International Institute of Anticancer Research</pub><pmid>36316042</pmid><doi>10.21873/cgp.20352</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-6177-1648</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1109-6535 |
| ispartof | Cancer genomics & proteomics, 2022-11, Vol.19 (6), p.692-702 |
| issn | 1109-6535 1790-6245 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9620446 |
| source | PubMed Central; EZB Electronic Journals Library |
| subjects | Biomarkers Cancer Cell migration Cell proliferation Endoplasmic reticulum Epithelium Gene expression Gene sequencing Golgi apparatus Immunohistochemistry Lipids Medical prognosis Ovarian cancer Proteins |
| title | TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A50%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TMED9%20Expression%20Level%20as%20a%20Biomarker%20of%20Epithelial%20Ovarian%20Cancer%20Progression%20and%20Prognosis&rft.jtitle=Cancer%20genomics%20&%20proteomics&rft.au=HAN,%20GWAN%20HEE&rft.date=2022-11-01&rft.volume=19&rft.issue=6&rft.spage=692&rft.epage=702&rft.pages=692-702&rft.issn=1109-6535&rft.eissn=1790-6245&rft_id=info:doi/10.21873/cgp.20352&rft_dat=%3Cproquest_pubme%3E2733415841%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2733415841&rft_id=info:pmid/36316042&rfr_iscdi=true |